Close
Biography
A clinical academic hepatologist with a specific interest in autoimmune liver disease. My particular areas are Primary Biliary Cirrhosis (PBC) and Autoimmune Hepatitis (AIH); conditions with real unmet need. Until recently I was the Dean of Research and Innovation in Newcastle (co-ordinating our successful REF 2014 submission) having previously established the Institute of Cellular Medicine in Newcastle. I have a long-standing interest in training and since July this year I have been the NIHR Dean for Faculty Trainees. I am an NIHR Senior Investigator and member of NIHR Strategy Board.
Research Interests
Having originally worked in the cellular immunology of PBC my research interests have evolved and followed the therapeutic application of knowledge in the disease. This has led to me developing additional programmes in PBC therapeutics, PROM development and symptom management where I am now seen as a leader internationally. I developed and lead the UK-PBC Stratified Medicine programme funded by the MRC and developed the UK-AIH platform funded by NIHR. These very large patient programmes with deep phenotyping of rare disease have underpinned the recent explosion of interest in novel therapeutics.
Key publications
Goldblatt J, Taylor PJS, Lipman T, Prince MI, Baragiotta A, Bassendine MF, James OFW, Jones DEJ. The true impact of fatigue in primary biliary cirrhosis: a population study. Gastroenterology 2002; 122:1235-41
Jacoby A, Rannard A, Buck D, Bhala N, Newton JL, James OFW, Jones DEJ. Development, validation and evaluation of the PBC-40: a disease specific health related quality of life measure for primary biliary cirrhosis. Gut 2005; 54:1622-1629
Mells, GF, Floyd JAB, Morley KI, Cordell HJ, Franklin CS, Shin S-Y, Heneghan MA, Neuberger JM, Donaldson PT, Day DB, Ducker SJ, Muriithi AW, Wheater EF, Hammond C, Dawwas M, The UK PBC Consortium, Wellcome Trust CCC, Jones DEJ, Peltonen L, Alexander GJ, Sandford RN, Anderson CA. Genome-wide association study identifies 13 additional susceptibility loci for primary biliary cirrhosis. Nature Genetics 2011:43:329-332
Liu JZ, Almarri MA, Gaffney DJ, Mells GF, Jostins L, Cordell HJ, Ducker S, Day D, Heneghan MA, Neuberger JM, Donaldosn PT, Bathgate A, Burroughs A, Davies M, Jones DEJ, Alexander GJ, Barrett JC, The UK-PBC Consortium, The Wellcome Trust case Control Consortium 3, Sandford RN, Anderson CA. Dense fine-mapping study identifies novel disease loci and implicates coding and non-coding variation in primary biliary cirrhosis risk. Nat Genet 2012: 44:1137-1141
Carbone M, Mells G, Pells G, Dawas MF, Newton JL, Heneghan M, Neuberger JM, Day D, Ducker SJ, UK-PBC Research Consortium, Sandford R, Alexander G, Jones DEJ. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid. Gastronterology 2013: 144:560-569
